Author

Lukas Egli

University of Zurich

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Anne EugsteriD· 1 shared Benjamin KasendaiD· 1 shared Christoph SchultheißiD· 1 shared Claudia FischeriD· 1 shared Corinne C. WidmeriD· 1 shared Dominik Heim· 1 shared Heinz Philipp LaubliiD· 1 shared Jakob Robert PasswegiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Anne EugsterORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

IGLV3-21-R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia

Claudia Fischer, Shih‐Shih Chen, Johanna Nimmerfroh, Anne Eugster, Simon Stücheli, Christoph Schultheiß, Corinne C. Widmer, Dominik Heim, Benjamin Kasenda, Jakob Robert Passweg, Sebastian Kobold, Lukas Egli, Nicolò Coianiz, Obinna Chijioke, Nicholas Chiorazzi, , Mascha Binder

This study develops bispecific antibodies targeting IGLV3-21R110 to selectively kill high-risk CLL cells while sparing healthy B cells and stem cells.

Haematologica · Sep 11, 2025Peer-reviewedCancer Biology